Rhythm PharmaceuticalsRYTM
Recorded

Rhythm Pharmaceuticals 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration26 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul MatteisAnalyst

All right, great. Thanks very much. Happy to be here with Hunter Smith, CFO of Rhythm Pharmaceuticals. I'm sure folks know the story well, but I think to just level set, I'll have you, Hunter, maybe just briefly give us a quick update on what you just talked about with how the IMCIVREE launch is going in HO, and then we can dig into that, and then we'll talk about PWS.

Hunter SmithCFO

How does that sound? That sounds great.

Hunter SmithCFO

First of all, thank you to Paul and the entire Stifel team for this conference, which is always a highlight of the year. It's a great location. There's always great swag. I was expecting a S'well bottle. I don't know if that's what I'm getting this year or not, but expectations are- You'll get a vest, and you'll like it.

Hunter SmithCFO

Okay. Expectations are high. Expectations are high. No, really happy to be here, and it is a very exciting time for Rhythm. Most of you are paying close attention. We just announced our third quarter results last week, and I would say we were super enthusiastic about the way our launch in acquired HO, hypothalamic obesity, is going thus far. We were approved back in March, and last week we reported over 700 start forms launched to date, and we had around 500 unique HCPs that wrote prescriptions for IMCIVREE in AHO, of which 25% were repeat prescribers. We think that breadth across a number of 700 start forms is a really terrific number, because most of those physicians come from our top two tiers of endocrinologists that we've been calling on, and that means they have multiple HO patients in their practice, right?

Hunter SmithCFO

That's a very strong launch base to build off of. That number of over 300 in the second quarter, very aligned with what our expectation has been. If you back out the clinical trial patients that we had in Q2 and Q3, we think we've seen that pace continue through October in Q4, and we have every reason to expect it will continue beyond that. Very pleased about that. Second item we'd want to highlight is we were approved in October, middle of last month, for acquired hypothalamic obesity in Japan. Very exciting opportunity. The Japanese environment, Japanese regulatory and reimbursement authorities have really charted a change in the path to address the drug lag that the market was feeling, a path very different to what we're seeing in developed Europe. Very positive reception for our efforts for IMCIVREE there.

Hunter SmithCFO

We've identified over 1,000 patients with AHO in Japan, and we have started launch and have patients on therapy. We've cautioned folks to have modest expectations for the first 12 months, because first 12 months post-launch, there are restrictions on the duration of prescriptions, so patients have to return to their HCP every two weeks to get prescriptions renewed. That's burdensome both to the patient and the HCP. That's designed for enhanced monitoring of a new therapy. Once that lifts, we expect the real trajectory of the launch to take hold, but obviously that's going to take a little while.

Hunter SmithCFO

The third major thing that we talked about at the quarter was we announced an amendment to our licensing agreement for bivamelagon, where we made a fixed payment, or committed to a fixed payment of $350 million over four years to buy down the bivamelagon royalty from somewhere in the 5%-7% range to 1% flat with our partners, LG. That, I think, is a statement about how strongly we feel about the potential of biva as a therapy. Despite our best efforts, there were some disincentives to further development, economic disincentives to further development of biva that were inherent in that licensing agreement, and this amendment gets rid of those.

Hunter SmithCFO

Now we have every incentive to be full speed ahead with biva, both in HO, but also, just as importantly, in Prader-Willi syndrome, where we've said that biva will go first among our next-gen assets in studying Prader-Willi syndrome, and we hope to meet with the FDA next year. Secondly, hopefully get to starting of a hyperphagia-focused study in patients with PWS in 2027.

Paul MatteisAnalyst

Excellent. I am with you that the dispersion of the prescriber base is a very, very interesting kind of leading indicator, not just for there's going to be broad adoption, but also just the implication of how many patients that are out there. From a physician behavior perspective, are most of these physicians kind of calling in patients to write the drug, or is this kind of coming up in sort of the natural course of visits that would have already might have happened?

Hunter SmithCFO

From what I have been learning from our commercial team and what they've been sharing in both market research and actual field experience, first of all, it speaks to the fundamental capacity challenges that endocrinology faces as a specialty. Endocrinologists are very, very busy. I think even in the major metros in the country, they book out more than a year. They book out a year in advance. Many of them are closed to new patients unless they have very severe conditions. Endocrinology is a very constrained specialty. The result of that, as we understand it, is that they tend to add patients as they come in for their updating their hormonal supplementation that has occurred in concomitant with, or concurrently with their AHO.

Hunter SmithCFO

Many of them have a diabetes insipidus or hypopituitarism or some other forms of hormonal deficits that occur as a result of the treatment for their underlying tumor. That means that even if a physician is well-educated on the disease, has diagnosed patients, and is ready to prescribe IMCIVREE, there may not be a movement of that patient up in the queue until they're coming in on a regularly scheduled basis. That's just a natural governor on uptake, even if there's a lot of desire for adoption.

Paul MatteisAnalyst

Yeah. Okay. But I guess ultimately, that dynamic, is that part of what underlies your confidence that the run rate you're seeing roughly could be sustainable?

Paul MatteisAnalyst

Absolutely. Okay. Makes sense. I know you have not formally updated that 2,000 patient number.

Paul MatteisAnalyst

You have just said, "Hey, it is higher and continues to increase." As it relates to the 700 or so start forms, can you at least speak qualitatively to the mix of these patients that are either going on therapy or are likely to go on therapy that maybe you did not actually know were identified before pre-launch?

Hunter SmithCFO

Yes. There is a couple of different components. One is the vast majority of the patients are coming from prescriptions written by tiered physicians. So physicians we were targeting when we started the launch. That is a good fact pattern. In BBS, for example, where we launched in 2022, we regularly had about a third of patients that were what we call fly-ins, i.e., the prescription just comes in, often from primary care, because the BBS patients were scattered, usually one patient in one specific practice in most cases, right? These patients are much more concentrated in endocrinology, and these patients are also these physicians tend to be ones we are already calling on. So, I do not want to say that all of the patients were identified, but I do want to say the bulk of them came from physicians that were in our target group, right?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day